Track topics on Twitter Track topics that are important to you
Osaka, Japan, August 2, 2016, and Leuven, Belgium, August 2, 2016 – Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) and TiGenix NV (Euronext Brussels: TIG) (“TiGenix”) today announced that the 24-week results of the Phase 3 ADMIRE-CD trial
Original Article: Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn's DiseaseNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...